Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts

Overview

Journal J Med Chem

Publisher American Chemical Society

Specialty Chemistry

Date 2018 Aug 15

PMID 30106578

Citations 59

Authors

Eric A Wold

Jianping Chen

Kathryn A Cunningham

Jia Zhou

Affiliations

Soon will be listed here.

Abstract

G-protein-coupled receptors (GPCRs) have been tractable drug targets for decades with over one-third of currently marketed drugs targeting GPCRs. Of these, the class A GPCR superfamily is highly represented, and continued drug discovery for this family of receptors may provide novel therapeutics for a vast range of diseases. GPCR allosteric modulation is an innovative targeting approach that broadens the available small molecule toolbox and is proving to be a viable drug discovery strategy, as evidenced by recent FDA approvals and clinical trials. Numerous class A GPCR allosteric modulators have been discovered recently, and emerging trends such as the availability of GPCR crystal structures, diverse functional assays, and structure-based computational approaches are improving optimization and development. This Perspective provides an update on allosterically targeted class A GPCRs and their disease indications and the medicinal chemistry approaches toward novel allosteric modulators and highlights emerging trends and opportunities in the field.

Citing Articles

Molecular Basis of PAC1R Allosteric Modulation with Lipids in Membranes.

Hamilton N, Yang B, Xiang C, Li T, Schneebeli S, Li J bioRxiv. 2025; .

PMID: 39974954 PMC: 11838235. DOI: 10.1101/2025.01.27.635027.

Identification of a Cannabinoid Receptor 2 Allosteric Site Using Computational Modeling and Pharmacological Analysis.

Farooq Z, Delre P, Iliadis S, Mangiatordi G, Contino M, Howell L ACS Pharmacol Transl Sci. 2025; 8(2):423-434.

PMID: 39974643 PMC: 11833715. DOI: 10.1021/acsptsci.4c00547.

Advances in cannabinoid receptors pharmacology: from receptor structural insights to ligand discovery.

Shen S, Wu C, Yang Z, Wang K, Shao Z, Yan W Acta Pharmacol Sin. 2025; .

PMID: 39910211 DOI: 10.1038/s41401-024-01472-9.

An Unexpected Activity of a Minor Cannabinoid: Cannabicyclol (CBL) Is a Potent Positive Allosteric Modulator of Serotonin 5-HT Receptor.

Haghdoost M, DePorre Y, Figi M, Young S, Krebs C, Bonn-Miller M J Nat Prod. 2025; 88(1):58-66.

PMID: 39811943 PMC: 11774245. DOI: 10.1021/acs.jnatprod.4c00977.

Unraveling GPCRs Allosteric Modulation. Cannabinoid 1 Receptor as a Case Study.

Cruz A, Warshel A Proteins. 2024; 93(4):763-785.

PMID: 39584635 PMC: 11879764. DOI: 10.1002/prot.26762.

References

Davoren J, ONeil S, Anderson D, Brodney M, Chenard L, Dlugolenski K . Design and optimization of selective azaindole amide M1 positive allosteric modulators. Bioorg Med Chem Lett. 2015; 26(2):650-655. DOI: 10.1016/j.bmcl.2015.11.053. View

Salovich J, Vinson P, Sheffler D, Lamsal A, Utley T, Blobaum A . Discovery of N-(4-methoxy-7-methylbenzo[d]thiazol-2-yl)isonicatinamide, ML293, as a novel, selective and brain penetrant positive allosteric modulator of the muscarinic 4 (M4) receptor. Bioorg Med Chem Lett. 2012; 22(15):5084-8. PMC: 3401285. DOI: 10.1016/j.bmcl.2012.05.109. View

Croy C, Schober D, Xiao H, Quets A, Christopoulos A, Felder C . Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. Mol Pharmacol. 2014; 86(1):106-15. DOI: 10.1124/mol.114.091751. View

Dror R, Green H, Valant C, Borhani D, Valcourt J, Pan A . Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature. 2013; 503(7475):295-9. DOI: 10.1038/nature12595. View

Price M, Baillie G, Thomas A, Stevenson L, Easson M, Goodwin R . Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol. 2005; 68(5):1484-95. DOI: 10.1124/mol.105.016162. View

Steen A, Larsen O, Thiele S, Rosenkilde M . Biased and g protein-independent signaling of chemokine receptors. Front Immunol. 2014; 5:277. PMC: 4066200. DOI: 10.3389/fimmu.2014.00277. View

Romagnoli R, Baraldi P, IJzerman A, Massink A, Cruz-Lopez O, Lopez-Cara L . Synthesis and biological evaluation of novel allosteric enhancers of the A1 adenosine receptor based on 2-amino-3-(4'-chlorobenzoyl)-4-substituted-5-arylethynyl thiophene. J Med Chem. 2014; 57(18):7673-86. DOI: 10.1021/jm5008853. View

Kenakin T . Biased signalling and allosteric machines: new vistas and challenges for drug discovery. Br J Pharmacol. 2011; 165(6):1659-1669. PMC: 3372820. DOI: 10.1111/j.1476-5381.2011.01749.x. View

Foord S, Bonner T, Neubig R, Rosser E, Pin J, Davenport A . International Union of Pharmacology. XLVI. G protein-coupled receptor list. Pharmacol Rev. 2005; 57(2):279-88. DOI: 10.1124/pr.57.2.5. View

10.

Wood M, Hopkins C, Brogan J, Conn P, Lindsley C . "Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology. Biochemistry. 2011; 50(13):2403-10. PMC: 3792571. DOI: 10.1021/bi200129s. View

11.

Thiele S, Malmgaard-Clausen M, Engel-Andreasen J, Steen A, Rummel P, Nielsen M . Modulation in selectivity and allosteric properties of small-molecule ligands for CC-chemokine receptors. J Med Chem. 2012; 55(18):8164-77. DOI: 10.1021/jm301121j. View

12.

Khurana L, Fu B, Duddupudi A, Liao Y, Immadi S, Kendall D . Pyrimidinyl Biphenylureas: Identification of New Lead Compounds as Allosteric Modulators of the Cannabinoid Receptor CB. J Med Chem. 2017; 60(3):1089-1104. PMC: 5724760. DOI: 10.1021/acs.jmedchem.6b01448. View

13.

Davoren J, Garnsey M, Pettersen B, Brodney M, Edgerton J, Fortin J . Design and Synthesis of γ- and δ-Lactam M Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M-Selective PAM with Weak Agonist Activity. J Med Chem. 2017; 60(15):6649-6663. DOI: 10.1021/acs.jmedchem.7b00597. View

14.

Romagnoli R, Baraldi P, Carrion M, Cara C, Cruz-Lopez O, Iaconinoto M . Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine receptor. J Med Chem. 2008; 51(18):5875-9. DOI: 10.1021/jm800586p. View

15.

Sliwoski G, Schubert M, Stichel J, Weaver D, Beck-Sickinger A, Meiler J . Discovery of Small-Molecule Modulators of the Human Y4 Receptor. PLoS One. 2016; 11(6):e0157146. PMC: 4905667. DOI: 10.1371/journal.pone.0157146. View

16.

Amarandi R, Hjorto G, Rosenkilde M, Karlshoj S . Probing Biased Signaling in Chemokine Receptors. Methods Enzymol. 2016; 570:155-86. DOI: 10.1016/bs.mie.2015.09.001. View

17.

Oswald C, Rappas M, Kean J, Dore A, Errey J, Bennett K . Intracellular allosteric antagonism of the CCR9 receptor. Nature. 2016; 540(7633):462-465. DOI: 10.1038/nature20606. View

18.

Lin D, Guo Q, Luo J, Zhang J, Nguyen K, Chen M . Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor. Mol Pharmacol. 2012; 82(5):843-59. PMC: 3477236. DOI: 10.1124/mol.112.079640. View

19.

Ghoshal A, Rook J, Dickerson J, Roop G, Morrison R, Jalan-Sakrikar N . Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model. Neuropsychopharmacology. 2015; 41(2):598-610. PMC: 5130135. DOI: 10.1038/npp.2015.189. View

20.

Brox R, Milanos L, Saleh N, Baumeister P, Buschauer A, Hofmann D . Molecular Mechanisms of Biased and Probe-Dependent Signaling at CXC-Motif Chemokine Receptor CXCR3 Induced by Negative Allosteric Modulators. Mol Pharmacol. 2018; 93(4):309-322. DOI: 10.1124/mol.117.110296. View